Designing out pollution in drug manufacture

The implementation of integrated pollution prevention and control (IPPC) has opened up a debate over whether it will drive pharmaceutical firms to reduce the impacts of developing and manufacturing new drugs. James Richens talks to AstraZeneca and GlaxoSmithKline to find out more

Sign in to continue

Sign in

Trouble signing in?

Reset password: Click here

Email: report@ends.co.uk

Call: 020 8267 8120

Register for
Free Trial

  • 14 day access to subscriber-only content

Register

Subscribe

Prices on request

  • Full access to endsreport.com for 12 months
  • Monthly print issues
  • Clear and accessible guidance on relevant legislation
  • Integration with ENDS Compliance Manager helping you plan ahead and ensure compliance for your organisation
  • Individual or bespoke multi-user packages available

See all benefits